7 completed, 2 recruiting, 1 terminated, 1 unknown. 2 Not applicable, 2 Phase 1, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Antipsychotic Agents: new trials by email Literature Review of Antipsychotic Agents trials Research Report on Antipsychotic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum Schizophrenia, Psychosis | Completed | University of Liverpool | 168 | 2023-08-01 | 2026-04-07 | |
| Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy PARTNER intervention, Control intervention - Deprescriptions, Antidepressive Agents | Not applicable | Recruiting | Ludwig-Maximilians - University of Munich | 352 | 2023-03-25 | 2025-05-04 |
| "Extended" (Alternate Day) Antipsychotic Dosing Risperidone, Olanzapine, paliperidone - Schizophrenia and Related Disorders, Drug Administration Schedule | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 120 | 2022-06-06 | 2026-04-13 |
| Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 89 | 2021-09-08 | 2024-03-19 |
| Relative Bioavailability of LY03010 Compared to Listed Drug LY03010; paliperidone palmitate, INVEGA SUSTENNA - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 281 | 2021-01-13 | 2023-04-25 |
| Clozapine Induced Weight Gain No study intervention - observational study - Weight Gain, Antipsychotic Agents | Unknown | Cwm Taf University Health Board (NHS) | 160 | 2020-03-01 | 2019-06-24 | |
| Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs) - Schizophrenia; Psychosis, Metabolic Syndrome | Phase 4 | Completed | Taichung Veterans General Hospital | 30 | 2019-12-19 | 2021-05-24 |
| Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia Pyridoxine, Placebo - Tardive Dyskinesia, Antipsychotic Agents | Not applicable | Completed | University of North Carolina, Chapel Hill | 17 | 2017-12-01 | 2023-03-14 |
| Pharmacoepigenetics of Bipolar Disorder Treatment Antipsychotic Agents, Bipolar Disorder | Completed | Wayne State University | 40 | 2015-11-01 | 2018-02-14 | |
| Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) Preladenant, Placebo, Anticholinergic agents or propanolol - Akathisia, Drug-Induced, Antipsychotic Agents | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 46 | 2007-08-15 | 2018-11-07 |
| A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR) Risperdal Consta - Schizophrenia, Tranquilizing Agents | Completed | Janssen Korea, Ltd., Korea | 230 | 2004-12-01 | 2014-04-03 |
Schizophrenia (6) · Psychotic Disorders (5) · Mental Disorders (3) · Mood Disorders (2) · Movement Disorders (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Akathisia, Drug-Induced (1) · Bipolar Disorder (1) · Breast Feeding (1) · Central Nervous System Diseases (1) · Dyskinesias (1) · Mania (1) · Metabolic Syndrome (1) · Neurologic Manifestations (1) · Signs and Symptoms (1)
Mental Disorders (5) · Schizophrenia Spectrum and Other Psychotic Disorders (5) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (3) · Behavior (2) · Central Nervous System Diseases (2) · Neurologic Manifestations (2) · Bipolar and Related Disorders (1) · Body Weight (1) · Body Weight Changes (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Dyskinesia, Drug-Induced (1) · Dyskinesias (1)
Paliperidone Palmitate (3) · Risperidone (2) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (1) · Cholinergic Antagonists (1) · Flupenthixol (1) · Haloperidol (1) · Olanzapine (1) · Propranolol (1) · Pyridoxine (1) · Sugars (1) · Vitamin B 6 (1)
Luye Pharma Group Ltd. (2) · Centre for Addiction and Mental Health (1) · Cwm Taf University Health Board (NHS) (1) · Janssen Korea, Ltd., Korea (1) · Ludwig-Maximilians - University of Munich (1) · Merck Sharp & Dohme LLC (1) · Taichung Veterans General Hospital (1) · University of Liverpool (1) · University of North Carolina, Chapel Hill (1) · Wayne State University (1)
United States (4) · Canada (1) · Germany (1) · Nigeria (1) · Taiwan (1) · United Kingdom (1)
Rui Li, MD (2) · Adeniyi Olagunju, PhD (1) · Brian P Tennant, PhD (1) · Chia-Jui Tsai, M.D. (1) · Gary J Remington, MD, PhD (1) · Kyle J Burghardt, PharmD (1) · Lars F Jarskog, MD (1) · Tobias Dreischulte, Prof. Dr. (1)